Publications

5808 Results

Serum phospholipid fatty acids and prostate cancer risk: results from the Prostate Cancer Prevention Trial. PMID21518693; PMC3145396

Authors
TM Brasky;E White;M Neuhouser;IM Thompson;X Song;C Till;A Kristal
Journal / Conference
American Journal of Epidemiology 173(12):1429-1439;
Year
2011
Research Committee(s)
Cancer Control
Study Number(s)
SWOG-9217

S0356: A phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma [PMID22025151;PMC3236655]

Authors
LP Leichman;B Goldman;C Thomas;K Billingsley;C Corless;J Benedetti;HJ Lenz;S Iqbal;P Gold;CD Blanke
Journal / Conference
Journal of Clinical Oncology, 29(34):4555-4560; 2011 Oct 24 [Epub ahead of print];
Year
2011
Research Committee(s)
Gastrointestinal
Study Number(s)
S0356

Colorectal chemoprevention pilot study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions [PMID21782524;NIHMS326411]

Authors
D Chu;M Hussey;D Alberts;F Meyskens;C Fenoglio-Preiser;S Rivkin;G Mills;J Giguere;C Blanke;G Goodman
Journal / Conference
Clinical Colorectal Cancer 10(4):310-316;
Year
2011
Research Committee(s)
Gastrointestinal
Study Number(s)
SWOG-9041

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: SWOG study S0605

Authors
M Sekeres;H Gundacker;J Lancet;A Advani;S Petersdorf;J Liesveld;D Mulford;T Norwood;C Willman;A List;F Appelbaum
Journal / Conference
Blood 118(3):523-528;
Year
2011
Research Committee(s)
Leukemia
Study Number(s)
S0605

First analysis of SWOG S0221: A phase III trial comparing chemotherapy schedules in high risk early breast cancer

Authors
GT Budd;WE Barlow;HCF Moore;TJ Hobday;JA Stewart;C Isaacs;M Salim;JK Cho;K Rinn;KS Albain;HK Chew;GV Burton;TD Moore;G Srkalovic;BA McGregor;LE Flaherty;RB Livingston;D Lew;J Gralow;G Hortobagyi
Journal / Conference
Journal of Clinical Oncology 29: 2011 (suppl; abstr 1004); ASCO 2011 meeting, oral presentation
Year
2011
Research Committee(s)
Breast
Study Number(s)
S0221

SWOG S1007: a phase III, randomized clinical trial of standard adjuvant endocrine therapy +/- chemotherapy in patients with 1-2 positive nodes, hormone receptor (HR)-positive and HER2-negative breast cancer with recurrence score (RS) of 25 or less

Authors
AM Gonzalez-Angulo;WE Barlow;J Gralow;F Meric-Bernstam;DF Hayes;CM Moinpour;SD Ramsey;A Schott;D Sparks;KS Albain;G Hortobagyi
Journal / Conference
Journal of Clinical Oncology 29: 2011 (suppl; abstr TPS104); ASCO Meeting, TIP poster
Year
2011
Research Committee(s)
Breast
Study Number(s)
S1007

Pilot study (SWOG S0429) of weekly cetuximab and chest radiotherapy (RT) for poor-risk stage III non-small cell lung cancer (NSCLC)

Authors
Y Chen;J Moon;KJ Pandya;K Kelly;L Gaspar;DHM Lau;FR Hirsch;DR Gandara
Journal / Conference
Journal of Clinical Oncology 29: 2011 (suppl; abstr 7040); ASCO 2011 meeting, general poster presentation
Year
2011
Research Committee(s)
Lung
Study Number(s)
S0429

Expression of topoisomerase II isoforms a and B in adult patients with acute myeloid leukemia (AML): relationship to immunophenotype and treatment outcome

Authors
A Michelson;K Kopecky;E Koegle;J Anderson;J Godwin;S Petersdorf;A List;C Willman;F Appelbaum;J Radich;M Ganapathi;R Ganapathi;A Advani
Journal / Conference
Journal of Clinical Oncology 29:(suppl; abstr 6564) ASCO 2011 meeting, general poster presentation
Year
2011
Research Committee(s)
Leukemia
Study Number(s)
SWOG-9031, SWOG-9126, SWOG-9333, SWOG-9500

Effect of vitamin E and selenium on rate of decline in FEV1: the respiratory ancillary study to the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Authors
P Cassano;K Guertin;A Kristal;K Arnold;J Crowley;JA Hartline;P Goodman;C Tangen;L Minasian;S Lippman;E Klein
Journal / Conference
American Journal of Respiratory & Critical Care Medicine 183:A6419:2011; American Thoracic Society 2011 Meeting, poster discussion;
Year
2011
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S0000C

Randomized phase III US/Canadian intergroup trial (SWOG S9704) comparing CHOP+/- R x 8 vs. CHOP +/- R x 6 followed by high dose therapy and autotransplant for patients with diffuse aggressive non-Hodgkin's lymphoma (NHL) in the high-intermediate (H-Int) or high IPI risk groups

Authors
P Stiff;J Unger;J Cook;L Constine;S Couban;T Shea;JN Winter;TP Miller;RR Tubbs;D Marcellus;J Friedberg;K Barton;G Mills;M LeBlanc;L Rimsza;S Forman;RI Fisher
Journal / Conference
Journal of Clinical Oncology 29:(suppl; abstr 8001); ASCO 2011 Annual Meeting, oral presentation
Year
2011
Research Committee(s)
Lymphoma
Study Number(s)
S9704